PeptideSearch

NAD+

Tested in people

Get notified when the evidence changes.

It has been tested in people, but it is not an approved medicine. The studies are usually small.

Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-05-14

Also called NAD / Nicotinamide Adenine Dinucleotide / NAD plus

A cell-fuel molecule, not a peptide. Sold as an IV drip or shot. Tested in people for aging and energy, with mixed results.

Nicotinamide riboside is a different molecule that the body turns into NAD+. Most trials that people call "NAD+ trials" gave this instead: see what the research shows on Nicotinamide Riboside.

Nicotinamide mononucleotide is the other building block the body turns into NAD+. It is swallowed, where NAD+ itself is usually given as a drip: see what the research shows on Nicotinamide Mononucleotide.

Official status: 503A Category 1 – nominated, still under FDA evaluation · Checked 2026-05-14

Can a doctor prescribe this?

Small pharmacy (503A)
Category 1 — under review, allowed for now
Large outsourcing facility (503B)
Never put forward to FDA

Not an FDA-approved medicine. The FDA has put "Nicotinamide Adenine Dinucleotide (NAD)" in Category 1 of the substances it is still working through for small-pharmacy (503A) compounding. While that review runs, the FDA says it does not plan to act against a pharmacy that makes it. That is not the same as being on the final list, which is set by rulemaking.

503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.

What happens next

A reading of which NAD forms the FDA 503B entries cover before any status is published for large outsourcing facilities.

The 503B document names "Beta-Nicotinamide Adenine Dinucleotide" in Category 1 and "Beta-nicotinamide adenine dinucleotide disodium salt, trihydrate" in Category 3. Those are different chemical forms in different categories, so one flat status would misstate at least one of them.

Lab suppliers we list: 16

Doses used in research

Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.

This is a sample, not the whole literature.

About 277,000 papers mentioning this compound have been published. We show a selected sample of 99 of them, not the full literature. How we choose them · count checked 2026-08-23

Spot an error? corrections@peptidesearch.org

What has happened so far

  1. 14 May 2026503A

    FDA lists "Nicotinamide Adenine Dinucleotide (NAD)" under 503A Category 1: Bulk Drug Substances Under Evaluation. Category 1 means FDA does not intend to take action against a pharmacy compounding it while the evaluation continues. It is not on the final 503A Bulks List. Read from the FDA 503A category document headed "Updated May 14, 2026". Salt and beta forms appear elsewhere in the document and are not treated as separate listings for NAD+.

    FDA

We'll email you when a new study, trial or status change lands for NAD+. Unsubscribe in one click.